Thailand
Vietnam
Taiwan
South Korea
Philippines
Singapore
Indonesia
USA
Heal Venture Lab is a venture builder community focused on bringing capital and outcome-driven medical innovations to Asia Pacific to improve on healthcare access and affordability. The company is creating a regional accelerator with focus on biomed product and service innovations on critical unmet epidemiology while creating a hub and spoke network for Asia with Singapore as the central hub.
High-risk early-stage platforms and “Drug Factories.”
→ Option Value & Convexity
→ 10x – 30x ROI Target
→ Power Law Fund Returner
Clinical value inflections (Phase 1b to Phase 2 PoC).
→ De-risking Inflection
→ 3x – 7x ROI Target
→ Primary M&A Exit Zone
Late-stage Medtech, Diagnostics, or Digital Health.
→ Capital Preservation
→ ~2x ROI Target
→ DPI & Velocity Focus
Singapore-based venture builder community focused on bringing capital and medical innovation to the Asia-Pacific region, with social impact goals in mind.
Screening based on company information, TPP, DD questionnaire, and advisor feedback
Overall investment plan and strategy
Overall investment plan and strategy
To confirm all relevant information
Singapore-based venture builder community focused on bringing capital and medical innovation to the Asia-Pacific region, with social impact goals in mind.
Screening based on company information, TPP, DD questionnaire, and advisor feedback
Overall investment plan and strategy
Overall investment plan and strategy
To confirm all relevant information
Therapeutic areas and unmet medical needs
Affordability and accessibility
Outcome-driven, scalable, and sustainable ventures
Sector & Stage
Advanced medtech, biotech, and digital health
Early to growth stage
(pre-A to Series B)
Core Capabilities
Regulatory submission and reimbursement strategy
Clinical development and trial support
Manufacturing, distribution, and commercial partnerships
Market validation, unmet need mapping, regulatory planning
Study design, CRO/CRO access, reimbursement strategy
Fundraising, investor syndication, strategic exits
Study design, CRO/CRO access, reimbursement strategy
Partner introductions, manufacturing localization
